Stock SAVA CASSAVA SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Cassava Sciences, Inc.

Equities

SAVA

US14817C1071

Real-time Estimate Cboe BZX
Other stock markets
 20:03:01 01/05/2024 BST 		5-day change 1st Jan Change
22.16 USD +0.07% Intraday chart for Cassava Sciences, Inc. +6.70% -1.69%
04-29 North American Morning Briefing : Investors Brace -2- DJ
03-25 Cassava Sciences Announces Completion of Interim Safety Review for Alzheimer's Drug Candidate Simufilam MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cassava Sciences Announces Completion of Interim Safety Review for Alzheimer's Drug Candidate Simufilam
Cassava Sciences, Inc. Announces Completion of an Interim Safety Review of Oral Simufilam On-Going Phase 3 Trials
Cassava Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Cassava Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Cassava Sciences, Inc. Reports Results of Two-Year Clinical Safety Study of Simufilam, an Investigational Oral Drug for the Proposed Treatment of Alzheimer?s Disease Dementia
Social Buzz: Wallstreetbets Stocks Mostly Up Premarket; Cassava Sciences Poised to Rise, Tesla to Decline
Cassava Sciences, Inc. Announces Board Appointments
Cassava Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer?S Disease
Cassava Sciences Completes Patient Enrollment in Phase 3 Program of Simufilam in Alzheimer's Disease
Sector Update: Health Care Stocks Retreating Late Afternoon
Sector Update: Health Care
Cassava Sciences Says MRI Data Suggests Simufilam Not Linked to Amyloid-Related Imaging Abnormalities
Cassava Sciences Says MRI Data Suggests Simufilam Not Linked to Amyloid-Related Imaging Abnormalities
Cassava Sciences, Inc. Announces Positive Safety Findings Based on Interim Magnetic Resonance Imaging Brain Data from Alzheimer's Patients
Sector Update: Health Care Stocks Advance in Late Afternoon
Sector Update: Health Care Stocks Rising Friday Afternoon
Cassava Sciences Refutes 'Egregious Misconduct' Allegations in CUNY Report, Calls Findings 'Illegitimate'; Shares Slump
MORNING BRIEFING - USA/Asien
Cassava Sciences Completes Enrollment of 804 Participants for 12-Month Phase 3 Alzheimer's Trial
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SAVA Stock
  4. News Cassava Sciences, Inc.
  5. Other languages